Logotipo del repositorio
 

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Vista sencilla de ítem
dc.contributor.authorLei, Jieping
dc.contributor.authorRudolph, Anja
dc.contributor.authorMoysich, Kirsten B.
dc.contributor.authorRafiq, Sajjad
dc.contributor.authorBehrens, Sabine
dc.contributor.authorGoode, Ellen L.
dc.contributor.authorPharoah, Paul Pd
dc.contributor.authorSeibold, Petra
dc.contributor.authorFasching, Peter A.
dc.contributor.authorAndrulis, Irene L.
dc.contributor.authorKristensen, Vessela N.
dc.contributor.authorCouch, Fergus J.
dc.contributor.authorHamann, Ute
dc.contributor.authorHooning, Maartje J.
dc.contributor.authorNevanlinna, Heli
dc.contributor.authorEilber, Ursula
dc.contributor.authorBolla, Manjeet K.
dc.contributor.authorDennis, Joe
dc.contributor.authorWang, Qin
dc.contributor.authorLindblom, Annika
dc.contributor.authorMannermaa, Arto
dc.contributor.authorLambrechts, Diether
dc.contributor.authorGarcia Closas, Montserrat
dc.contributor.authorHall, Per
dc.contributor.authorChenevix Trench, Georgia
dc.contributor.authorShah, Mitul
dc.contributor.authorLuben, Robert
dc.contributor.authorHaeberle, Lothar
dc.contributor.authorEkici, Arif B.
dc.contributor.authorBeckmann, Matthias W.
dc.contributor.authorKnight, Julia A.
dc.contributor.authorGlendon, Gord
dc.contributor.authorTchatchou, Sandrine
dc.contributor.authorAlnaes, Grethe I. Grenaker
dc.contributor.authorBorresen Dale, Anne Lise
dc.contributor.authorNord, Silje
dc.contributor.authorOlson, Janet E.
dc.contributor.authorHallberg, Emily
dc.contributor.authorVachon, Celine
dc.contributor.authorTorres López, Diana María
dc.contributor.authorUlmer, Hans Ulrich
dc.contributor.authorRuediger, Thomas
dc.contributor.authorJager, Agnes
dc.contributor.authorvan Deurzen, Carolien Hm
dc.contributor.authorTilanus Linthorst, Madeleine MA
dc.contributor.authorMuranen, Taru A.
dc.contributor.authorAittomäki, Kristiina
dc.contributor.authorBlomqvist, Carl
dc.contributor.authorMargolin, Sara
dc.contributor.authorKosma, Veli Matti
dc.contributor.authorHartikainen, Jaana M.
dc.contributor.authorKataja, Vesa
dc.contributor.authorHatse, Sigrid
dc.contributor.authorWildiers, Hans
dc.contributor.authorSmeets, Ann
dc.contributor.authorFigueroa, Jonine
dc.contributor.authorChanock, Stephen J.
dc.contributor.authorLissowska, Jolanta
dc.contributor.authorLi, Jingmei
dc.contributor.authorHumphreys, Keith
dc.contributor.authorPhillips, Kelly Anne
dc.contributor.authorkConFab, Investigators
dc.contributor.authorLinn, Sabine
dc.contributor.authorCornelissen, Sten
dc.contributor.authorvan den Broek, Sandra Alexandra J.
dc.contributor.authorKang, Daehee
dc.contributor.authorChoi, Ji Yeob
dc.contributor.authorPark, Sue K.
dc.contributor.authorYoo, Keun Young
dc.contributor.authorHsiung, Chia Ni
dc.contributor.authorWu, Pei Ei
dc.contributor.authorHou, Ming Feng
dc.contributor.authorShen, Chen Yang
dc.contributor.authorTeo, Soo Hwang
dc.contributor.authorMohd Taib, Nur Aishah
dc.contributor.authorYip, Cheng Har
dc.contributor.authorHo, Gwo Fuang
dc.contributor.authorMatsuo, Keitaro
dc.contributor.authorIto, Hidemi
dc.contributor.authorIwata, Hiroji
dc.contributor.authorTajima, Kazuo
dc.contributor.authorDunning, Alison M.
dc.contributor.authorBenitez, Javier
dc.contributor.authorCzene, Kamila
dc.contributor.authorSucheston, Lara E.
dc.contributor.authorMaishman, Tom
dc.contributor.authorTappe, William J.
dc.contributor.authorEccles, Diana
dc.contributor.authorEaston, Douglas F.
dc.contributor.authorSchmidt, Marjanka K.
dc.contributor.authorChang Claude, Jenny
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana
dc.date.accessioned2020-03-11T12:45:15Z
dc.date.accessioned2020-04-15T13:32:52Z
dc.date.available2020-03-11T12:45:15Z
dc.date.available2020-04-15T13:32:52Z
dc.date.created2015-02-10
dc.description.abstractenglishIntroduction: Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen receptor (ER) negative breast cancer. To identify variants in immunosuppressive pathway genes associated with prognosis after adjuvant chemotherapy for ER-negative patients, we studied stage I-III invasive breast cancer patients of European ancestry, including 9,334 ER-positive (3,151 treated with chemotherapy) and 2,334 ER-negative patients (1,499 treated with chemotherapy). Methods: We pooled data from sixteen studies from the Breast Cancer Association Consortium (BCAC), and employed two independent studies for replications. Overall 3,610 single nucleotide polymorphisms (SNPs) in 133 genes were genotyped as part of the Collaborative Oncological Gene-environment Study, in which phenotype and clinical data were collected and harmonized. Multivariable Cox proportional hazard regression was used to assess genetic associations with overall survival (OS) and breast cancer-specific survival (BCSS). Heterogeneity according to chemotherapy or ER status was evaluated with the log-likelihood ratio test. Results: Three independent SNPs in TGFBR2 and IL12B were associated with OS (P <10−3) solely in ER-negative patients after chemotherapy (267 events). Poorer OS associated with TGFBR2 rs1367610 (G > C) (per allele hazard ratio (HR) 1.54 (95% confidence interval (CI) 1.22 to 1.95), P = 3.08 × 10−4 ) was not found in ER-negative patients without chemotherapy or ER-positive patients with chemotherapy (P for interaction <10−3). Two SNPs in IL12B (r2 = 0.20) showed different associations with ER-negative disease after chemotherapy: rs2546892 (G > A) with poorer OS (HR 1.50 (95% CI 1.21 to 1.86), P = 1.81 × 10−4 ), and rs2853694 (A > C) with improved OS (HR 0.73(95% CI 0.61 to 0.87), P = 3.67 × 10−4). Similar associations were observed with BCSS. Association with TGFBR2 rs1367610 but not IL12B variants replicated using BCAC Asian samples and the independent Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer Study and yielded a combined HR of 1.57 ((95% CI 1.28 to 1.94), P = 2.05 × 10−5) without study heterogeneity. Conclusions: TGFBR2 variants may have prognostic and predictive value in ER-negative breast cancer patients treated with adjuvant chemotherapy. Our findings provide further insights into the development of immunotherapeutic targets for ER-negative breast cancer.spa
dc.description.paginas1-13spa
dc.description.quartilescopusQ1spa
dc.description.quartilewosQ1spa
dc.description.tipoarticuloArtículo de investigaciónspa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.format.soportePapel / Electrónicospa
dc.identifierhttps://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0522-2spa
dc.identifier.doihttps://doi.org/10.1186/s13058-015-0522-2spa
dc.identifier.issn14655411 / 1465542X (Electrónico)spa
dc.identifier.urihttp://hdl.handle.net/10554/47561
dc.languagespaspa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceBreast Cancer Research; Vol. 17 (2015)spa
dc.subject.keywordOverall Survivalspa
dc.subject.keywordTreg Cellspa
dc.subject.keywordEstrogen Receptor Statusspa
dc.subject.keywordBreast Cancer Association Consortiumspa
dc.subject.keywordBreast Cancer Association Consortium Studyspa
dc.titleAssessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapyspa
dc.typeinfo:eu-repo/semantics/article
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Breast Cancer Research.pdf
Tamaño:
677.7 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Plain Text
Descripción:
Descargar

Colecciones

Artículos